Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.

@article{Hzode2012BoceprevirAT,
  title={Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.},
  author={Christophe H{\'e}zode},
  journal={Liver international : official journal of the International Association for the Study of the Liver},
  year={2012},
  volume={32 Suppl 1},
  pages={
          32-8
        }
}
Effective management of adverse events (AEs) is important to prevent treatment discontinuation and optimize hepatitis C virus infection eradication rates. The addition of direct-acting antiviral agents, telaprevir (TVR) or boceprevir to pegylated interferon (PEG-IFN) and ribavirin (RBV) represents a new era of therapy associated with an improvement in treatment response rates and an impairment of the safety profile compared to PEG-IFN/RBV. An increase in the frequency and severity of anaemia… CONTINUE READING
Highly Cited
This paper has 34 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 18 citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in the advance and illuminate phase 3 studies

  • MS Sulkowski, R Reddy, NH Afdhal
  • J Hepatol
  • 2011
2 Excerpts

Clinical pharmacology of BOC:metabolism, excretion, and drug-drug interactions

  • C Kassera, E Hughes, M Treitel
  • th Conference on Retroviruses and Opportunistic…
  • 2011